CryoLife Announces Release Date and Teleconference Call Details for The Fourth Quarter and Year Ended December 31, 2002

ATLANTA, Feb. 14 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, announced today that fourth quarter and year ended December 31, 2002 financial results will be released on Tuesday, February 25, 2003.

The Company also announced that following the release of financial results, a teleconference will be held promptly at 11:15 a.m. Eastern Time, February 25, 2003, hosted by Steven G. Anderson, CryoLife President and Chief Executive Officer.

Individuals interested in listening to the live teleconference may do so by calling 973-582-2700 a few minutes prior to 11:15 a.m. on February 25, 2003. No identification number is required. Those interested in listening to a replay of the teleconference may do so by calling (toll free) 877-519-4471 or 973-341-3080. The identification number for the replay is 3697824. The replay will be available February 25 through February 28, 2003.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular, vascular and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada and Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft vascular graft, which is CE marked for distribution within the European Community. The human heart valves and vascular grafts processed by CryoLife using the SynerGraft technology are distributed in the U.S. under the trade names of CryoValve(R)SG and CryoVein(R)SG, respectively.

For additional information about the company, visit CryoLife's web site: http://www.cryolife.com